After BioCryst fizzle, a new oral HAE player emerges
A new player in the search for an oral hereditary angioedema pill has received a major boost and show of confidence.
Pharvaris announced $66 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
